Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 4,000,000 shares, a growth of 151.6% from the November 30th total of 1,590,000 shares. Based on an average daily trading volume, of 93,440,000 shares, the short-interest ratio is presently 0.0 days. Currently, 2.1% of the company's stock are sold short.
Tonix Pharmaceuticals Stock Down 8.8 %
Shares of NASDAQ TNXP traded down $0.03 during trading hours on Friday, hitting $0.34. 73,979,242 shares of the stock were exchanged, compared to its average volume of 30,416,361. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $14.08. The firm has a fifty day moving average price of $0.22 and a 200-day moving average price of $0.41. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The company has a market cap of $63.10 million, a PE ratio of -0.01 and a beta of 2.23.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. On average, sell-side analysts expect that Tonix Pharmaceuticals will post -17.63 EPS for the current year.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research note on Monday. They set a "hold" rating for the company.
Get Our Latest Analysis on TNXP
Tonix Pharmaceuticals Company Profile
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Read More
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
